Industry
Biotechnology
Carisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.
Loading...
Open
1.08
Mkt cap
43M
Volume
206K
High
1.09
P/E Ratio
-0.62
52-wk high
3.16
Low
1.03
Div yield
N/A
52-wk low
0.80
Portfolio Pulse from Benzinga Newsdesk
June 28, 2024 | 11:23 am
Portfolio Pulse from Benzinga Newsdesk
June 28, 2024 | 11:00 am
Portfolio Pulse from Benzinga Newsdesk
June 27, 2024 | 8:35 pm
Portfolio Pulse from Benzinga Newsdesk
June 27, 2024 | 8:32 pm
Portfolio Pulse from Benzinga Insights
June 26, 2024 | 6:01 pm
Portfolio Pulse from Benzinga Newsdesk
June 26, 2024 | 4:22 pm
Portfolio Pulse from Benzinga Newsdesk
June 25, 2024 | 11:39 am
Portfolio Pulse from Benzinga Newsdesk
June 25, 2024 | 11:32 am
Portfolio Pulse from Benzinga Insights
May 17, 2024 | 3:01 pm
Portfolio Pulse from Benzinga Newsdesk
May 17, 2024 | 2:25 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.